{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:05:42Z","timestamp":1789067142514,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40123-025-01252-6","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:58:05Z","timestamp":1760695085000},"page":"3079-3091","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["One-Year Outcomes of Faricimab in Treatment-Na\u00efve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report"],"prefix":"10.1007","volume":"14","author":[{"given":"Anne","family":"Tillmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Stillenmunkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus G.","family":"Garweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Bartolomeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahm","family":"Spitznagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva C.","family":"De Oliveira Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Ambresin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moreno","family":"Menghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor M.","family":"Somfai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Zweifel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Fr\u00f6hlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Artemiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Ebneter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Hatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Weinberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel B.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Schild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Eandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6227-2242","authenticated-orcid":false,"given":"Marion R.","family":"Munk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Swiss Retina Research Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Feltgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Schaerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"2","key":"1252_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u201316.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"1252_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65.e5.","journal-title":"Ophthalmology"},{"issue":"2","key":"1252_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1252_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","volume":"4","author":"TA Ciulla","year":"2020","unstructured":"Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes. Ophthalmol Retina. 2020;4(1):19\u201330.","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"1252_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, Mitchell P, Finger RP, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128(2):234\u201347.","journal-title":"Ophthalmology"},{"issue":"4","key":"1252_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","volume":"160","author":"JL Prenner","year":"2015","unstructured":"Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol. 2015;160(4):725-31.e1.","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"1252_CR7","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","volume":"138","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Patel SS, Ferrone PJ, et al. Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase\u00a02 randomized clinical trial. JAMA Ophthalmol. 2020;138(9):964\u201372.","journal-title":"JAMA Ophthalmol"},{"issue":"10326","key":"1252_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16\u00a0weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase\u00a03, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"issue":"1","key":"1252_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40942-024-00566-0","volume":"10","author":"N Nasimi","year":"2024","unstructured":"Nasimi N, Nasimi S, Grauslund J, Vergmann AS, Subhi Y. Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review. Int J Retina Vitreous. 2024;10(1):48.","journal-title":"Int J Retina Vitreous"},{"key":"1252_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020385","author":"C Hara","year":"2024","unstructured":"Hara C, Suzue M, Fujimoto S, et al. Comparison of loading dose between aflibercept and faricimab for neovascular age-related macular degeneration. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13020385.","journal-title":"J Clin Med"},{"issue":"2","key":"1252_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00417-023-06241-8","volume":"262","author":"M Maruyama-Inoue","year":"2024","unstructured":"Maruyama-Inoue M, Yanagi Y, Inoue T, Kadonosono K. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262(2):589\u201399.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"1252_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10384-023-01040-4","volume":"68","author":"H Matsumoto","year":"2024","unstructured":"Matsumoto H, Hoshino J, Nakamura K, Akiyama H. One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-na\u00efve neovascular age-related macular degeneration. Jpn J Ophthalmol. 2024;68(2):83\u201390.","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"1252_CR13","doi-asserted-by":"publisher","first-page":"8747","DOI":"10.1038\/s41598-023-35759-4","volume":"13","author":"R Mukai","year":"2023","unstructured":"Mukai R, Kataoka K, Tanaka K, et al. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci Rep. 2023;13(1):8747.","journal-title":"Sci Rep"},{"key":"1252_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2147\/OPTH.S448507","volume":"18","author":"A Tanaka","year":"2024","unstructured":"Tanaka A, Hata M, Tsuchikawa M, et al. Short-term outcomes of 3\u00a0monthly intravitreal faricimab on different subtypes of neovascular age-related macular degeneration. Clin Ophthalmol. 2024;18:507\u201316.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"1252_CR15","doi-asserted-by":"publisher","first-page":"11681","DOI":"10.1038\/s41598-024-62559-1","volume":"14","author":"R Mukai","year":"2024","unstructured":"Mukai R, Kataoka K, Tanaka K, et al. One-year outcomes and safety assessment of faricimab in treatment-na\u00efve patients with neovascular age-related macular degeneration in Japan. Sci Rep. 2024;14(1):11681.","journal-title":"Sci Rep"},{"key":"1252_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/life14020193","author":"B Ng","year":"2024","unstructured":"Ng B, Kolli H, Ajith Kumar N, et al. Real-world data on faricimab switching in treatment-refractory neovascular age-related macular degeneration. Life (Basel). 2024. https:\/\/doi.org\/10.3390\/life14020193.","journal-title":"Life (Basel)"},{"issue":"15","key":"1252_CR17","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","volume":"37","author":"PE Stanga","year":"2023","unstructured":"Stanga PE, Valent\u00edn-Bravo FJ, Stanga SEF, Reinstein UI, Pastor-Idoate S, Downes SM. Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye (Lond). 2023;37(15):3282\u20139.","journal-title":"Eye (Lond)"},{"issue":"7","key":"1252_CR18","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s00417-024-06421-0","volume":"262","author":"M Schneider","year":"2024","unstructured":"Schneider M, Bjerager J, Hodzic-Hadzibegovic D, Klefter ON, Subhi Y, Hajari J. Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262(7):2153\u201362.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"1252_CR19","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00417-023-06319-3","volume":"262","author":"G Grimaldi","year":"2024","unstructured":"Grimaldi G, Cancian G, Rizzato A, et al. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study. Graefes Arch Clin Exp Ophthalmol. 2024;262(4):1151\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"1252_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","volume":"8","author":"R Raimondi","year":"2024","unstructured":"Raimondi R, Falfeli T, Bogdanova-Bennet A, et al. Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab. Ophthalmol Retina. 2024;8(6):537\u201344.","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"1252_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00586-w","volume":"10","author":"G Grimaldi","year":"2024","unstructured":"Grimaldi G, Cancian G, Paris A, Clerici M, Volpe G, Menghini M. Intravitreal faricimab for treatment na\u00efve patients with neovascular age-related macular degeneration: a real-world prospective study. Int J Retina Vitreous. 2024;10(1):70.","journal-title":"Int J Retina Vitreous"},{"issue":"7","key":"1252_CR22","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing Snellen visual acuity measurements. Retina. 2010;30(7):1046\u201350.","journal-title":"Retina"},{"issue":"3","key":"1252_CR23","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1167\/iovs.05-0981","volume":"47","author":"K Schulze-Bonsel","year":"2006","unstructured":"Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual acuities \u201chand motion\u201d and \u201ccounting fingers\u201d can be quantified with the Freiburg visual acuity test. Invest Ophthalmol Vis Sci. 2006;47(3):1236\u201340.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1252_CR24","doi-asserted-by":"crossref","unstructured":"Ambati NR, Leone A, Brill D, Sisk RA. Real-world long-term outcomes of intravitreal faricimab in previously treated chronic neovascular age-related macular degeneration. Retina. 2025;45(3):446\u201353.","DOI":"10.1097\/IAE.0000000000004322"},{"issue":"1","key":"1252_CR25","doi-asserted-by":"publisher","first-page":"9087","DOI":"10.1038\/s41598-024-59894-8","volume":"14","author":"H Takahashi","year":"2024","unstructured":"Takahashi H, Inoda S, Takahashi H, et al. One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment. Sci Rep. 2024;14(1):9087.","journal-title":"Sci Rep"}],"updated-by":[{"DOI":"10.1007\/s40123-026-01319-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000}}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01252-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01252-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01252-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T20:16:11Z","timestamp":1772396171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01252-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01252-6","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to incorrect figure legends in the article. Now, the figure legends has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40123-026-01319-y","URL":"https:\/\/doi.org\/10.1007\/s40123-026-01319-y","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gabriela Grimaldi: consultant for Apellis, Bayer, Roche. Lecturer for Abbvie, Apellis, Bayer, Roche. Grant support from Bayer and Roche. G\u00e1bor M. Somfai: consultant for Apellis, Allergan, Bayer, Novartis, Roche. Lecturer for Apellis, Allergan, Bayer, Novartis, Roche, Carl Zeiss Meditec. Justus G. Garweg: Consultancies and Lectures for AbbVie, Apellis, Bayer. Novartis, Roche Andreas Ebneter: Consultant for Apellis, Bayer, Roche, former employee of F. Hoffmann-La Roche Ltd. Andreas Weinberger: Consultancies and Lectures for Apellis, Bayer. Novartis, Roche Marion R. Munk: consultant for Apellis, Abbvie, Acuccela, Bayer, Roche, Lumithera, Novartis, Ocuterra, Alimera, Zeiss, Ocular therapeutix, Isarna, RetinAI, Dandelion, Optos, Oculis, Lumithera, Kubota, Eyepoint, Avecida Therapeutics, Astellas, Genesight Therapeutics. Anne Tillmann, Richard Stillenmunkes, Jennifer Cattaneo, Nicol\u00f2 Bartolomeo, Tahm Spitznagel, Eva C De Oliveira Figueiredo, Aude Ambresin, Moreno Menghini, Sandrine Zweifel, Jacqueline Fr\u00f6hlich, Dmitri Artemiev, Katja Hatz, Isabel B. Pfister, Chiara Eandi, Christin Schild has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by all participating ethics committees, led by the ethics committee of the canton of Berne (registration no. 2024-01026). Coded patient data were included on the basis of general or specific informed consent, in line with ICH-GCP E6, the Declaration of Helsinki, and Swiss law.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}